アルツハイマー病治療の世界市場2023年~2027年

◆英語タイトル:Global Alzheimers Disease Therapeutics Market 2023-2027

Technavioが発行した調査報告書(IRTNTR40742-23)◆商品コード:IRTNTR40742-23
◆発行会社(リサーチ会社):Technavio
◆発行日:2023年3月15日
◆ページ数:約120
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:北米、ヨーロッパ、アジア、その他地域
◆産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥380,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥608,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

テクナビオ社では、世界のアルツハイマー病治療市場規模が2022年から2027年の間に4,391.9百万ドルに拡大すると予測しており、予測期間中に年平均8.91%成長する見通しです。本調査資料ではアルツハイマー病治療の世界市場について調査・分析を行い、エグゼクティブサマリー、市場状況、市場規模予測、過去の市場規模、ファイブフォース分析、薬物クラス別(コリンエステラーゼ阻害剤、N-メチル-D-アスパラギン酸受容体拮抗薬、その他)分析、流通チャネル別(病院薬局、小売薬局、Eコマース薬局)分析、地域別(北米、ヨーロッパ、アジア、その他地域、アメリカ、カナダ、イギリス、ドイツ、日本)分析、顧客状況、推進要因・課題・動向、企業状況、企業分析など、以下のように掲載しています。また、企業情報として、AB Science SA, AbbVie Inc., AgeneBio Inc., Aurobindo Pharma Ltd., Biogen Inc., Denali Therapeutics Inc., Eisai Co. Ltd., Eli Lilly and Co., Grifols SA, H Lundbeck AS, Johnson and Johnson Services Inc., Neuronascent Inc., Novartis AG, Shanghai Green Valley Pharmaceuticals Co. Ltd., Spinogenix Inc., T3D Therapeutics, Teva Pharmaceutical Industries Ltd., Viatris Inc., Vivoryon Therapeutics N.V., Lupin Ltd.などが含まれています。
・エグゼクティブサマリー
・市場状況
・市場規模予測
・過去の市場規模
・ファイブフォース分析
・世界のアルツハイマー病治療市場規模:薬物クラス別
- コリンエステラーゼ阻害剤の市場規模
- N-メチル-D-アスパラギン酸受容体拮抗薬の市場規模
- その他薬物クラスの市場規模
・世界のアルツハイマー病治療市場規模:流通チャネル別
- 病院薬局チャネルの市場規模
- 小売薬局チャネルの市場規模
- Eコマース薬局チャネルの市場規模
・顧客状況
・世界のアルツハイマー病治療市場規模:地域別
- 北米のアルツハイマー病治療市場規模
- ヨーロッパのアルツハイマー病治療市場規模
- アジアのアルツハイマー病治療市場規模
- その他地域のアルツハイマー病治療市場規模
- アメリカのアルツハイマー病治療市場規模
- カナダのアルツハイマー病治療市場規模
- イギリスのアルツハイマー病治療市場規模
- ドイツのアルツハイマー病治療市場規模
- 日本のアルツハイマー病治療市場規模
・推進要因・課題・動向
・企業状況
・企業分析

テクナビオ社は、利益・価格・競争・プロモーションなどの主なパラメーターを分析することにより、複数の情報源からのデータを調査・統合・統括することで、アルツハイマー病治療市場の詳細な全体像を提示します。主要産業のインフルエンサーを特定することにより、多様な市場の側面を提示します。これらのデータは包括的​​且つ信頼性が高く、一次・二次の広範な調査の結果です。テクナビオ社の市場調査資料は、正確なアルツハイマー病治療市場の成長を予測するため、定性的・定量的調査により徹底的な競合状況、詳細に及ぶベンダー選定&分析を提供します。

アルツハイマー病治療の世界市場 2023-2027

Technavio社は、アルツハイマー病治療市場をモニターしており、2022年から2027年にかけて4,391.9百万ドルの成長が予測され、予測期間中のCAGRは8.91%で加速すると予測しています。当レポートでは、アルツハイマー病治療市場の全体的な分析、市場規模と予測、動向、成長促進要因、課題に加え、約25のベンダーを網羅したベンダー分析も提供しています。

当レポートでは、現在の市場シナリオ、最新動向と促進要因、市場環境全体に関する最新分析を提供しています。市場は、新規バイオマーカーの入手可能性、研究、開発、アルツハイマー病に対する認識の高まり、治療薬の承認に伴う強力なパイプラインによって牽引されています。

Technavioのアルツハイマー病治療市場は以下のようにセグメント化されています:

・薬剤クラス別:
– コリンエステラーゼ阻害薬
– N-メチル-D-アスパラギン酸受容体拮抗薬
– その他

・流通チャネル別:
– 病院薬局
– 小売薬局
– Eコマース薬局

・地域別:
– 北米
– ヨーロッパ
– アジア
– その他の地域(ROW)

本調査では、今後数年間のアルツハイマー病治療市場の成長を促進する主な理由の一つとして、再生療法の出現を挙げています。また、治療薬発見のための資金調達の増加や、高感度診断モダリティの利用可能性は、市場の大きな需要につながるでしょう。

Technavio社は、複数の情報源からのデータを調査、合成、要約し、主要パラメータの分析によって、市場の詳細な姿を提示します。

当レポートでは、アルツハイマー病治療市場について以下の分野をカバーしています:
– アルツハイマー病治療市場のサイジング
– アルツハイマー病治療市場予測
– アルツハイマー病治療市場の産業分析

Technavio社の確実なベンダー分析は、クライアントが市場でのポジションを向上できるように設計されており、これに沿って本レポートには、AB Science SA, AbbVie Inc., AgeneBio Inc., Aurobindo Pharma Ltd., Biogen Inc., Denali Therapeutics Inc., Eisai Co. Ltd., Eli Lilly and Co., Grifols SA, H Lundbeck AS, Johnson and Johnson Services Inc., Neuronascent Inc., Novartis AG, Shanghai Green Valley Pharmaceuticals Co. Ltd., Spinogenix Inc., T3D Therapeutics, Teva Pharmaceutical Industries Ltd., Viatris Inc., Vivoryon Therapeutics N.V., and Lupin Ltdなどの企業情報が含まれています。また、アルツハイマー病治療市場の分析レポートには、市場成長に影響を与える今後の動向や課題に関する情報も含まれています。これは、企業が戦略を立て、来るべき成長機会をすべて活用するのに役立つものです。

本調査は、業界の主要参加者からのインプットを含め、一次情報と二次情報を客観的に組み合わせて実施しました。本レポートでは、主要ベンダーの分析に加え、包括的な市場およびベンダーの状況を掲載しています。

Technavioは、利益、価格、競争、プロモーションなどの主要パラメータの分析により、複数の情報源からのデータを調査、統合、要約する方法で、市場の詳細な姿を提示します。また、主要な業界インフルエンサーを特定することで、市場の様々な側面を提示します。提示されるデータは包括的で信頼性が高く、一次および二次にわたる広範な調査の結果です。Technavioの市場調査レポートは、正確な市場成長を予測するために、完全な競争環境と、質的・量的調査を用いた綿密なベンダー選定方法と分析を提供します。

❖ レポートの目次 ❖

• 1 Executive Summary
o 1.1 Market overview
o Exhibit 01: Executive Summary – Chart on Market Overview
o Exhibit 02: Executive Summary – Data Table on Market Overview
o Exhibit 03: Executive Summary – Chart on Global Market Characteristics
o Exhibit 04: Executive Summary – Chart on Market by Geography
o Exhibit 05: Executive Summary – Chart on Market Segmentation by Drug Class
o Exhibit 06: Executive Summary – Chart on Market Segmentation by Distribution Channel
o Exhibit 07: Executive Summary – Chart on Incremental Growth
o Exhibit 08: Executive Summary – Data Table on Incremental Growth
o Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
• 2 Market Landscape
o 2.1 Market ecosystem
o Exhibit 10: Parent market
o Exhibit 11: Market Characteristics
• 3 Market Sizing
o 3.1 Market definition
o Exhibit 12: Offerings of vendors included in the market definition
o 3.2 Market segment analysis
o Exhibit 13: Market segments
o 3.3 Market size 2022
o 3.4 Market outlook: Forecast for 2022-2027
o Exhibit 14: Chart on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
o Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
• 4 Historic Market Size
o 4.1 Global alzheimers disease therapeutics market 2017 – 2021
o Exhibit 18: Historic Market Size – Data Table on Global alzheimers disease therapeutics market 2017 – 2021 ($ million)
o 4.2 Drug class Segment Analysis 2017 – 2021
o Exhibit 19: Historic Market Size – Drug class Segment 2017 – 2021 ($ million)
o 4.3 Distributed channel Segment Analysis 2017 – 2021
o Exhibit 20: Historic Market Size – Distributed channel Segment 2017 – 2021 ($ million)
o 4.4 Geography Segment Analysis 2017 – 2021
o Exhibit 21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
o 4.5 Country Segment Analysis 2017 – 2021
o Exhibit 22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
• 5 Five Forces Analysis
o 5.1 Five forces summary
o Exhibit 23: Five forces analysis – Comparison between 2022 and 2027
o 5.2 Bargaining power of buyers
o Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
o 5.3 Bargaining power of suppliers
o Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
o 5.4 Threat of new entrants
o Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
o 5.5 Threat of substitutes
o Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
o 5.6 Threat of rivalry
o Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
o 5.7 Market condition
o Exhibit 29: Chart on Market condition – Five forces 2022 and 2027
• 6 Market Segmentation by Drug Class
o 6.1 Market segments
o Exhibit 30: Chart on Drug Class – Market share 2022-2027 (%)
o Exhibit 31: Data Table on Drug Class – Market share 2022-2027 (%)
o 6.2 Comparison by Drug Class
o Exhibit 32: Chart on Comparison by Drug Class
o Exhibit 33: Data Table on Comparison by Drug Class
o 6.3 Cholinesterase inhibitors – Market size and forecast 2022-2027
o Exhibit 34: Chart on Cholinesterase inhibitors – Market size and forecast 2022-2027 ($ million)
o Exhibit 35: Data Table on Cholinesterase inhibitors – Market size and forecast 2022-2027 ($ million)
o Exhibit 36: Chart on Cholinesterase inhibitors – Year-over-year growth 2022-2027 (%)
o Exhibit 37: Data Table on Cholinesterase inhibitors – Year-over-year growth 2022-2027 (%)
o 6.4 N-methyl-D-aspartate receptor antagonist – Market size and forecast 2022-2027
o Exhibit 38: Chart on N-methyl-D-aspartate receptor antagonist – Market size and forecast 2022-2027 ($ million)
o Exhibit 39: Data Table on N-methyl-D-aspartate receptor antagonist – Market size and forecast 2022-2027 ($ million)
o Exhibit 40: Chart on N-methyl-D-aspartate receptor antagonist – Year-over-year growth 2022-2027 (%)
o Exhibit 41: Data Table on N-methyl-D-aspartate receptor antagonist – Year-over-year growth 2022-2027 (%)
o 6.5 Others – Market size and forecast 2022-2027
o Exhibit 42: Chart on Others – Market size and forecast 2022-2027 ($ million)
o Exhibit 43: Data Table on Others – Market size and forecast 2022-2027 ($ million)
o Exhibit 44: Chart on Others – Year-over-year growth 2022-2027 (%)
o Exhibit 45: Data Table on Others – Year-over-year growth 2022-2027 (%)
o 6.6 Market opportunity by Drug Class
o Exhibit 46: Market opportunity by Drug Class ($ million)
o Exhibit 47: Data Table on Market opportunity by Drug Class ($ million)
• 7 Market Segmentation by Distribution Channel
o 7.1 Market segments
o Exhibit 48: Chart on Distribution Channel – Market share 2022-2027 (%)
o Exhibit 49: Data Table on Distribution Channel – Market share 2022-2027 (%)
o 7.2 Comparison by Distribution Channel
o Exhibit 50: Chart on Comparison by Distribution Channel
o Exhibit 51: Data Table on Comparison by Distribution Channel
o 7.3 Hospital pharmacy – Market size and forecast 2022-2027
o Exhibit 52: Chart on Hospital pharmacy – Market size and forecast 2022-2027 ($ million)
o Exhibit 53: Data Table on Hospital pharmacy – Market size and forecast 2022-2027 ($ million)
o Exhibit 54: Chart on Hospital pharmacy – Year-over-year growth 2022-2027 (%)
o Exhibit 55: Data Table on Hospital pharmacy – Year-over-year growth 2022-2027 (%)
o 7.4 Retail pharmacy – Market size and forecast 2022-2027
o Exhibit 56: Chart on Retail pharmacy – Market size and forecast 2022-2027 ($ million)
o Exhibit 57: Data Table on Retail pharmacy – Market size and forecast 2022-2027 ($ million)
o Exhibit 58: Chart on Retail pharmacy – Year-over-year growth 2022-2027 (%)
o Exhibit 59: Data Table on Retail pharmacy – Year-over-year growth 2022-2027 (%)
o 7.5 E-commerce pharmacy – Market size and forecast 2022-2027
o Exhibit 60: Chart on E-commerce pharmacy – Market size and forecast 2022-2027 ($ million)
o Exhibit 61: Data Table on E-commerce pharmacy – Market size and forecast 2022-2027 ($ million)
o Exhibit 62: Chart on E-commerce pharmacy – Year-over-year growth 2022-2027 (%)
o Exhibit 63: Data Table on E-commerce pharmacy – Year-over-year growth 2022-2027 (%)
o 7.6 Market opportunity by Distribution Channel
o Exhibit 64: Market opportunity by Distribution Channel ($ million)
o Exhibit 65: Data Table on Market opportunity by Distribution Channel ($ million)
• 8 Customer Landscape
o 8.1 Customer landscape overview
o Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 9 Geographic Landscape
o 9.1 Geographic segmentation
o Exhibit 67: Chart on Market share by geography 2022-2027 (%)
o Exhibit 68: Data Table on Market share by geography 2022-2027 (%)
o 9.2 Geographic comparison
o Exhibit 69: Chart on Geographic comparison
o Exhibit 70: Data Table on Geographic comparison
o 9.3 North America – Market size and forecast 2022-2027
o Exhibit 71: Chart on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 72: Data Table on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 73: Chart on North America – Year-over-year growth 2022-2027 (%)
o Exhibit 74: Data Table on North America – Year-over-year growth 2022-2027 (%)
o 9.4 Europe – Market size and forecast 2022-2027
o Exhibit 75: Chart on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 76: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 77: Chart on Europe – Year-over-year growth 2022-2027 (%)
o Exhibit 78: Data Table on Europe – Year-over-year growth 2022-2027 (%)
o 9.5 Asia – Market size and forecast 2022-2027
o Exhibit 79: Chart on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 80: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 81: Chart on Asia – Year-over-year growth 2022-2027 (%)
o Exhibit 82: Data Table on Asia – Year-over-year growth 2022-2027 (%)
o 9.6 Rest of World (ROW) – Market size and forecast 2022-2027
o Exhibit 83: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 84: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 85: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o Exhibit 86: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o 9.7 US – Market size and forecast 2022-2027
o Exhibit 87: Chart on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 88: Data Table on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 89: Chart on US – Year-over-year growth 2022-2027 (%)
o Exhibit 90: Data Table on US – Year-over-year growth 2022-2027 (%)
o 9.8 Canada – Market size and forecast 2022-2027
o Exhibit 91: Chart on Canada – Market size and forecast 2022-2027 ($ million)
o Exhibit 92: Data Table on Canada – Market size and forecast 2022-2027 ($ million)
o Exhibit 93: Chart on Canada – Year-over-year growth 2022-2027 (%)
o Exhibit 94: Data Table on Canada – Year-over-year growth 2022-2027 (%)
o 9.9 UK – Market size and forecast 2022-2027
o Exhibit 95: Chart on UK – Market size and forecast 2022-2027 ($ million)
o Exhibit 96: Data Table on UK – Market size and forecast 2022-2027 ($ million)
o Exhibit 97: Chart on UK – Year-over-year growth 2022-2027 (%)
o Exhibit 98: Data Table on UK – Year-over-year growth 2022-2027 (%)
o 9.10 Germany – Market size and forecast 2022-2027
o Exhibit 99: Chart on Germany – Market size and forecast 2022-2027 ($ million)
o Exhibit 100: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
o Exhibit 101: Chart on Germany – Year-over-year growth 2022-2027 (%)
o Exhibit 102: Data Table on Germany – Year-over-year growth 2022-2027 (%)
o 9.11 Japan – Market size and forecast 2022-2027
o Exhibit 103: Chart on Japan – Market size and forecast 2022-2027 ($ million)
o Exhibit 104: Data Table on Japan – Market size and forecast 2022-2027 ($ million)
o Exhibit 105: Chart on Japan – Year-over-year growth 2022-2027 (%)
o Exhibit 106: Data Table on Japan – Year-over-year growth 2022-2027 (%)
o 9.12 Market opportunity by geography
o Exhibit 107: Market opportunity by geography ($ million)
o Exhibit 108: Data Tables on Market opportunity by geography ($ million)
• 10 Drivers, Challenges, and Trends
o 10.1 Market drivers
o 10.2 Market challenges
o 10.3 Impact of drivers and challenges
o Exhibit 109: Impact of drivers and challenges in 2022 and 2027
o 10.4 Market trends
• 11 Vendor Landscape
o 11.1 Overview
o 11.2 Vendor landscape
o Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
o 11.3 Landscape disruption
o Exhibit 111: Overview on factors of disruption
o 11.4 Industry risks
o Exhibit 112: Impact of key risks on business
• 12 Vendor Analysis
o 12.1 Vendors covered
o Exhibit 113: Vendors covered
o 12.2 Market positioning of vendors
o Exhibit 114: Matrix on vendor position and classification
o 12.3 AB Science SA
o Exhibit 115: AB Science SA – Overview
o Exhibit 116: AB Science SA – Product / Service
o Exhibit 117: AB Science SA – Key offerings
o 12.4 AbbVie Inc.
o Exhibit 118: AbbVie Inc. – Overview
o Exhibit 119: AbbVie Inc. – Product / Service
o Exhibit 120: AbbVie Inc. – Key news
o Exhibit 121: AbbVie Inc. – Key offerings
o 12.5 AgeneBio Inc.
o Exhibit 122: AgeneBio Inc. – Overview
o Exhibit 123: AgeneBio Inc. – Product / Service
o Exhibit 124: AgeneBio Inc. – Key offerings
o 12.6 Aurobindo Pharma Ltd.
o Exhibit 125: Aurobindo Pharma Ltd. – Overview
o Exhibit 126: Aurobindo Pharma Ltd. – Product / Service
o Exhibit 127: Aurobindo Pharma Ltd. – Key offerings
o 12.7 Biogen Inc.
o Exhibit 128: Biogen Inc. – Overview
o Exhibit 129: Biogen Inc. – Product / Service
o Exhibit 130: Biogen Inc. – Key offerings
o 12.8 Denali Therapeutics Inc.
o Exhibit 131: Denali Therapeutics Inc. – Overview
o Exhibit 132: Denali Therapeutics Inc. – Product / Service
o Exhibit 133: Denali Therapeutics Inc. – Key offerings
o 12.9 Eisai Co. Ltd.
o Exhibit 134: Eisai Co. Ltd. – Overview
o Exhibit 135: Eisai Co. Ltd. – Business segments
o Exhibit 136: Eisai Co. Ltd. – Key news
o Exhibit 137: Eisai Co. Ltd. – Key offerings
o Exhibit 138: Eisai Co. Ltd. – Segment focus
o 12.10 Eli Lilly and Co.
o Exhibit 139: Eli Lilly and Co. – Overview
o Exhibit 140: Eli Lilly and Co. – Product / Service
o Exhibit 141: Eli Lilly and Co. – Key offerings
o 12.11 Grifols SA
o Exhibit 142: Grifols SA – Overview
o Exhibit 143: Grifols SA – Business segments
o Exhibit 144: Grifols SA – Key offerings
o Exhibit 145: Grifols SA – Segment focus
o 12.12 H Lundbeck AS
o Exhibit 146: H Lundbeck AS – Overview
o Exhibit 147: H Lundbeck AS – Product / Service
o Exhibit 148: H Lundbeck AS – Key offerings
o 12.13 Johnson and Johnson Services Inc.
o Exhibit 149: Johnson and Johnson Services Inc. – Overview
o Exhibit 150: Johnson and Johnson Services Inc. – Business segments
o Exhibit 151: Johnson and Johnson Services Inc. – Key news
o Exhibit 152: Johnson and Johnson Services Inc. – Key offerings
o Exhibit 153: Johnson and Johnson Services Inc. – Segment focus
o 12.14 Lupin Ltd.
o Exhibit 154: Lupin Ltd. – Overview
o Exhibit 155: Lupin Ltd. – Product / Service
o Exhibit 156: Lupin Ltd. – Key news
o Exhibit 157: Lupin Ltd. – Key offerings
o 12.15 Novartis AG
o Exhibit 158: Novartis AG – Overview
o Exhibit 159: Novartis AG – Business segments
o Exhibit 160: Novartis AG – Key offerings
o Exhibit 161: Novartis AG – Segment focus
o 12.16 Teva Pharmaceutical Industries Ltd.
o Exhibit 162: Teva Pharmaceutical Industries Ltd. – Overview
o Exhibit 163: Teva Pharmaceutical Industries Ltd. – Business segments
o Exhibit 164: Teva Pharmaceutical Industries Ltd. – Key news
o Exhibit 165: Teva Pharmaceutical Industries Ltd. – Key offerings
o Exhibit 166: Teva Pharmaceutical Industries Ltd. – Segment focus
o 12.17 Viatris Inc.
o Exhibit 167: Viatris Inc. – Overview
o Exhibit 168: Viatris Inc. – Business segments
o Exhibit 169: Viatris Inc. – Key offerings
o Exhibit 170: Viatris Inc. – Segment focus
• 13 Appendix
o 13.1 Scope of the report
o 13.2 Inclusions and exclusions checklist
o Exhibit 171: Inclusions checklist
o Exhibit 172: Exclusions checklist
o 13.3 Currency conversion rates for US$
o Exhibit 173: Currency conversion rates for US$
o 13.4 Research methodology
o Exhibit 174: Research methodology
o Exhibit 175: Validation techniques employed for market sizing
o Exhibit 176: Information sources
o 13.5 List of abbreviations
o Exhibit 177: List of abbreviations

Exhibits:
Exhibits1: Executive Summary – Chart on Market Overview
Exhibits2: Executive Summary – Data Table on Market Overview
Exhibits3: Executive Summary – Chart on Global Market Characteristics
Exhibits4: Executive Summary – Chart on Market by Geography
Exhibits5: Executive Summary – Chart on Market Segmentation by Drug Class
Exhibits6: Executive Summary – Chart on Market Segmentation by Distribution Channel
Exhibits7: Executive Summary – Chart on Incremental Growth
Exhibits8: Executive Summary – Data Table on Incremental Growth
Exhibits9: Executive Summary – Chart on Vendor Market Positioning
Exhibits10: Parent market
Exhibits11: Market Characteristics
Exhibits12: Offerings of vendors included in the market definition
Exhibits13: Market segments
Exhibits14: Chart on Global – Market size and forecast 2022-2027 ($ million)
Exhibits15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits18: Historic Market Size – Data Table on Global alzheimers disease therapeutics market 2017 – 2021 ($ million)
Exhibits19: Historic Market Size – Drug class Segment 2017 – 2021 ($ million)
Exhibits20: Historic Market Size – Distributed channel Segment 2017 – 2021 ($ million)
Exhibits21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
Exhibits22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
Exhibits23: Five forces analysis – Comparison between 2022 and 2027
Exhibits24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
Exhibits25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
Exhibits26: Threat of new entrants – Impact of key factors in 2022 and 2027
Exhibits27: Threat of substitutes – Impact of key factors in 2022 and 2027
Exhibits28: Threat of rivalry – Impact of key factors in 2022 and 2027
Exhibits29: Chart on Market condition – Five forces 2022 and 2027
Exhibits30: Chart on Drug Class – Market share 2022-2027 (%)
Exhibits31: Data Table on Drug Class – Market share 2022-2027 (%)
Exhibits32: Chart on Comparison by Drug Class
Exhibits33: Data Table on Comparison by Drug Class
Exhibits34: Chart on Cholinesterase inhibitors – Market size and forecast 2022-2027 ($ million)
Exhibits35: Data Table on Cholinesterase inhibitors – Market size and forecast 2022-2027 ($ million)
Exhibits36: Chart on Cholinesterase inhibitors – Year-over-year growth 2022-2027 (%)
Exhibits37: Data Table on Cholinesterase inhibitors – Year-over-year growth 2022-2027 (%)
Exhibits38: Chart on N-methyl-D-aspartate receptor antagonist – Market size and forecast 2022-2027 ($ million)
Exhibits39: Data Table on N-methyl-D-aspartate receptor antagonist – Market size and forecast 2022-2027 ($ million)
Exhibits40: Chart on N-methyl-D-aspartate receptor antagonist – Year-over-year growth 2022-2027 (%)
Exhibits41: Data Table on N-methyl-D-aspartate receptor antagonist – Year-over-year growth 2022-2027 (%)
Exhibits42: Chart on Others – Market size and forecast 2022-2027 ($ million)
Exhibits43: Data Table on Others – Market size and forecast 2022-2027 ($ million)
Exhibits44: Chart on Others – Year-over-year growth 2022-2027 (%)
Exhibits45: Data Table on Others – Year-over-year growth 2022-2027 (%)
Exhibits46: Market opportunity by Drug Class ($ million)
Exhibits47: Data Table on Market opportunity by Drug Class ($ million)
Exhibits48: Chart on Distribution Channel – Market share 2022-2027 (%)
Exhibits49: Data Table on Distribution Channel – Market share 2022-2027 (%)
Exhibits50: Chart on Comparison by Distribution Channel
Exhibits51: Data Table on Comparison by Distribution Channel
Exhibits52: Chart on Hospital pharmacy – Market size and forecast 2022-2027 ($ million)
Exhibits53: Data Table on Hospital pharmacy – Market size and forecast 2022-2027 ($ million)
Exhibits54: Chart on Hospital pharmacy – Year-over-year growth 2022-2027 (%)
Exhibits55: Data Table on Hospital pharmacy – Year-over-year growth 2022-2027 (%)
Exhibits56: Chart on Retail pharmacy – Market size and forecast 2022-2027 ($ million)
Exhibits57: Data Table on Retail pharmacy – Market size and forecast 2022-2027 ($ million)
Exhibits58: Chart on Retail pharmacy – Year-over-year growth 2022-2027 (%)
Exhibits59: Data Table on Retail pharmacy – Year-over-year growth 2022-2027 (%)
Exhibits60: Chart on E-commerce pharmacy – Market size and forecast 2022-2027 ($ million)
Exhibits61: Data Table on E-commerce pharmacy – Market size and forecast 2022-2027 ($ million)
Exhibits62: Chart on E-commerce pharmacy – Year-over-year growth 2022-2027 (%)
Exhibits63: Data Table on E-commerce pharmacy – Year-over-year growth 2022-2027 (%)
Exhibits64: Market opportunity by Distribution Channel ($ million)
Exhibits65: Data Table on Market opportunity by Distribution Channel ($ million)
Exhibits66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits67: Chart on Market share by geography 2022-2027 (%)
Exhibits68: Data Table on Market share by geography 2022-2027 (%)
Exhibits69: Chart on Geographic comparison
Exhibits70: Data Table on Geographic comparison
Exhibits71: Chart on North America – Market size and forecast 2022-2027 ($ million)
Exhibits72: Data Table on North America – Market size and forecast 2022-2027 ($ million)
Exhibits73: Chart on North America – Year-over-year growth 2022-2027 (%)
Exhibits74: Data Table on North America – Year-over-year growth 2022-2027 (%)
Exhibits75: Chart on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits76: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits77: Chart on Europe – Year-over-year growth 2022-2027 (%)
Exhibits78: Data Table on Europe – Year-over-year growth 2022-2027 (%)
Exhibits79: Chart on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits80: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits81: Chart on Asia – Year-over-year growth 2022-2027 (%)
Exhibits82: Data Table on Asia – Year-over-year growth 2022-2027 (%)
Exhibits83: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits84: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits85: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits86: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits87: Chart on US – Market size and forecast 2022-2027 ($ million)
Exhibits88: Data Table on US – Market size and forecast 2022-2027 ($ million)
Exhibits89: Chart on US – Year-over-year growth 2022-2027 (%)
Exhibits90: Data Table on US – Year-over-year growth 2022-2027 (%)
Exhibits91: Chart on Canada – Market size and forecast 2022-2027 ($ million)
Exhibits92: Data Table on Canada – Market size and forecast 2022-2027 ($ million)
Exhibits93: Chart on Canada – Year-over-year growth 2022-2027 (%)
Exhibits94: Data Table on Canada – Year-over-year growth 2022-2027 (%)
Exhibits95: Chart on UK – Market size and forecast 2022-2027 ($ million)
Exhibits96: Data Table on UK – Market size and forecast 2022-2027 ($ million)
Exhibits97: Chart on UK – Year-over-year growth 2022-2027 (%)
Exhibits98: Data Table on UK – Year-over-year growth 2022-2027 (%)
Exhibits99: Chart on Germany – Market size and forecast 2022-2027 ($ million)
Exhibits100: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
Exhibits101: Chart on Germany – Year-over-year growth 2022-2027 (%)
Exhibits102: Data Table on Germany – Year-over-year growth 2022-2027 (%)
Exhibits103: Chart on Japan – Market size and forecast 2022-2027 ($ million)
Exhibits104: Data Table on Japan – Market size and forecast 2022-2027 ($ million)
Exhibits105: Chart on Japan – Year-over-year growth 2022-2027 (%)
Exhibits106: Data Table on Japan – Year-over-year growth 2022-2027 (%)
Exhibits107: Market opportunity by geography ($ million)
Exhibits108: Data Tables on Market opportunity by geography ($ million)
Exhibits109: Impact of drivers and challenges in 2022 and 2027
Exhibits110: Overview on Criticality of inputs and Factors of differentiation
Exhibits111: Overview on factors of disruption
Exhibits112: Impact of key risks on business
Exhibits113: Vendors covered
Exhibits114: Matrix on vendor position and classification
Exhibits115: AB Science SA – Overview
Exhibits116: AB Science SA – Product / Service
Exhibits117: AB Science SA – Key offerings
Exhibits118: AbbVie Inc. – Overview
Exhibits119: AbbVie Inc. – Product / Service
Exhibits120: AbbVie Inc. – Key news
Exhibits121: AbbVie Inc. – Key offerings
Exhibits122: AgeneBio Inc. – Overview
Exhibits123: AgeneBio Inc. – Product / Service
Exhibits124: AgeneBio Inc. – Key offerings
Exhibits125: Aurobindo Pharma Ltd. – Overview
Exhibits126: Aurobindo Pharma Ltd. – Product / Service
Exhibits127: Aurobindo Pharma Ltd. – Key offerings
Exhibits128: Biogen Inc. – Overview
Exhibits129: Biogen Inc. – Product / Service
Exhibits130: Biogen Inc. – Key offerings
Exhibits131: Denali Therapeutics Inc. – Overview
Exhibits132: Denali Therapeutics Inc. – Product / Service
Exhibits133: Denali Therapeutics Inc. – Key offerings
Exhibits134: Eisai Co. Ltd. – Overview
Exhibits135: Eisai Co. Ltd. – Business segments
Exhibits136: Eisai Co. Ltd. – Key news
Exhibits137: Eisai Co. Ltd. – Key offerings
Exhibits138: Eisai Co. Ltd. – Segment focus
Exhibits139: Eli Lilly and Co. – Overview
Exhibits140: Eli Lilly and Co. – Product / Service
Exhibits141: Eli Lilly and Co. – Key offerings
Exhibits142: Grifols SA – Overview
Exhibits143: Grifols SA – Business segments
Exhibits144: Grifols SA – Key offerings
Exhibits145: Grifols SA – Segment focus
Exhibits146: H Lundbeck AS – Overview
Exhibits147: H Lundbeck AS – Product / Service
Exhibits148: H Lundbeck AS – Key offerings
Exhibits149: Johnson and Johnson Services Inc. – Overview
Exhibits150: Johnson and Johnson Services Inc. – Business segments
Exhibits151: Johnson and Johnson Services Inc. – Key news
Exhibits152: Johnson and Johnson Services Inc. – Key offerings
Exhibits153: Johnson and Johnson Services Inc. – Segment focus
Exhibits154: Lupin Ltd. – Overview
Exhibits155: Lupin Ltd. – Product / Service
Exhibits156: Lupin Ltd. – Key news
Exhibits157: Lupin Ltd. – Key offerings
Exhibits158: Novartis AG – Overview
Exhibits159: Novartis AG – Business segments
Exhibits160: Novartis AG – Key offerings
Exhibits161: Novartis AG – Segment focus
Exhibits162: Teva Pharmaceutical Industries Ltd. – Overview
Exhibits163: Teva Pharmaceutical Industries Ltd. – Business segments
Exhibits164: Teva Pharmaceutical Industries Ltd. – Key news
Exhibits165: Teva Pharmaceutical Industries Ltd. – Key offerings
Exhibits166: Teva Pharmaceutical Industries Ltd. – Segment focus
Exhibits167: Viatris Inc. – Overview
Exhibits168: Viatris Inc. – Business segments
Exhibits169: Viatris Inc. – Key offerings
Exhibits170: Viatris Inc. – Segment focus
Exhibits171: Inclusions checklist
Exhibits172: Exclusions checklist
Exhibits173: Currency conversion rates for US$
Exhibits174: Research methodology
Exhibits175: Validation techniques employed for market sizing
Exhibits176: Information sources
Exhibits177: List of abbreviations



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ アルツハイマー病治療の世界市場2023年~2027年(Global Alzheimers Disease Therapeutics Market 2023-2027)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆